Phage therapy

F. Laurent, PU-PH/ C. Kolenda, PHU/F. Laumay, MCU

To address the challenge of treatment failure, we combined innovative strategies to isolate, characterise, select, produce, purify, and formulate virulent phages for clinical use.

The PPR-AMR PHAG-ONE project and the RHU THERAPhage project focused on:

• A comprehensive phenotypic and molecular understanding of phage activity to improve therapeutic efficacy and adapt phages to overcome bacterial resistance mechanisms
• Deciphering the dynamics between phages and bacterial cells to better target therapeutic regimens
• Investigating the molecular and cellular mechanisms underlying bacterial resistance to phages to inform strategies that improve the robustness of phage therapy
• Development of in vivo models (Galleria mellonella, zebrafish, rabbit) to enable high-throughput screening of phage activity and preclinical evaluation of therapeutic efficacy against Staphylococcus species